The pathology of intermediate-risk non-muscle-invasive bladder cancer is less well-defined than both high-risk and low-risk presentations of this disease. Recently reported guidelines seek to aid clinicians in classification of intermediate-risk patients, and also provide treatment recommendations for this subgroup.
